EKF (EKF) News
Follow EKF (EKF) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
EKF: Flat revenue, higher margins, and strong H2 outlook drive confidence for full-year 2026
Resilient H1 2026 results featured flat revenue at GBP 25 million, improved margins, and 26% EPS growth. Strong order book and operational progress support confidence in a robust H2 and full-year outlook, with ongoing in
EARNINGS | Sep 15, 2026, 04:40 PM UTC
L
EKF: Resilient H1 2026 results, improved margins, and strong outlook driven by strategic execution
Revenue held steady at GBP 25 million in H1 2026, with gross margin up to 53% and adjusted EBITDA rising 2.4% to GBP 5.9 million. Operational progress included a key U.S. blood bank contract, a strategic rebrand, and tar
EARNINGS | Sep 15, 2026, 04:25 PM UTC
L
EKF: EPS up 26% on flat revenue, with strong Life Sciences growth and robust H2 outlook
H1 2026 saw flat revenue at £25.0m, improved gross margin to 53%, and a 26% rise in EPS, supported by share buybacks. Point-of-Care is set for H2 growth, while Life Sciences and contract manufacturing delivered strong ga
EARNINGS | Sep 15, 2026, 08:32 AM UTC
H
EKF: Stable H1 2026 results with improved margins, strong Life Sciences growth, and robust outlook
Revenue and gross margin remained stable in H1 2026, with adjusted EBITDA growth and strong Life Sciences performance. The order book supports confidence in meeting FY 2026 guidance, while share buybacks and strategic in
EARNINGS | Sep 15, 2026, 06:13 AM UTC
L
UK's EKF Diagnostics H1 revenue flat, gross margin rises
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 15, 2026, 06:10 AM UTC
H
EKF: Stable H1 2026 results with improved margins and strong outlook for H2 and FY 2026
Revenue and gross margin remained stable in H1 2026, with Life Sciences driving growth and Point-of-Care set for recovery in H2. Adjusted EBITDA rose 2.4%, and the company remains confident in meeting FY 2026 guidance, s
EARNINGS | Sep 15, 2026, 06:02 AM UTC
L
REG - EKF Diagnostics Hldg - Interim Results
RNS Number: 7166U EKF Diagnostics Holdings PLC 15 September 2026 EKF Diagnostics Holdings plc(“EKF” or the “Company”, or the “Group”)Interim Results for the six months ended 30 June 2026Stable H1 revenue, increased gross
NEWS | Sep 15, 2026, 06:00 AM UTC
L
EKF Diagnostics buys back 50,000 ordinary shares
EKF Diagnostics Holdings plc announces it has purchased 50,000 of its ordinary shares of 1p each as part of a share buyback.
EQUITY | Sep 03, 2026, 06:00 AM UTC
L
EKF Diagnostics Holding announces share buyback
EKF Diagnostics Holding has announced a share buyback.
EQUITY | Sep 01, 2026, 06:01 AM UTC
L
EKF Diagnostics Holding announces share buyback
EKF Diagnostics Holding has announced a share buyback.
EQUITY | Aug 27, 2026, 08:39 AM UTC